$300 Million is the total value of Decheng Capital Management III (Cayman), LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals Inc. | $42,117,635 | -28.9% | 2,099,583 | 0.0% | 14.06% | -24.3% | |
| RCUS | Arcus Biosciences, Inc | $15,612,731 | -11.6% | 869,790 | 0.0% | 5.21% | -6.0% | |
| TXG | 10x Genomics, Inc. | $14,831,603 | -26.1% | 359,554 | 0.0% | 4.95% | -21.4% | |
| ARGX | Argenx SE | $13,484,919 | +26.1% | 27,429 | 0.0% | 4.50% | +34.2% | |
| PACB | Pacific Biosciences of California, Inc. | $12,223,331 | -37.2% | 1,463,872 | 0.0% | 4.08% | -33.2% | |
| ILMN | Illumnia, Inc. | $11,100,324 | -26.8% | 80,859 | 0.0% | 3.70% | -22.1% | |
| HZNP | Horizon Therapeutics PLC | $9,127,941 | +12.5% | 78,900 | 0.0% | 3.05% | +19.7% | |
| PHAT | PHATHOM PHARMACEUTICALS INC | $8,814,500 | -27.6% | 850,000 | 0.0% | 2.94% | -22.9% | |
| Cue Health Inc. | $3,969,798 | +19.5% | 8,980,909 | 0.0% | 1.32% | +27.2% | ||
| TERN | Terns Pharmaceuticals, Inc. | $3,592,854 | -42.5% | 714,285 | 0.0% | 1.20% | -38.8% | |
| EQ | Equillium Inc. | $3,291,008 | -1.3% | 4,447,308 | 0.0% | 1.10% | +5.0% | |
| Aadi Bioscience, Inc. | $2,547,432 | -29.2% | 526,329 | 0.0% | 0.85% | -24.7% | ||
| SCYX | Scynexis Inc. | $1,266,665 | -22.7% | 555,555 | 0.0% | 0.42% | -17.7% | |
| MRSN | Mersana Therapeutics, Inc. | $1,148,420 | -61.4% | 904,268 | 0.0% | 0.38% | -58.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-12-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.